相关临床试验
11
7 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
7
63.6%
已完成
4
36.4%
- Amarin's revenue has declined from $285 million two years ago to $183 million in 2025, primarily due to generic competition facing its sole drug Vascepa in the US market. - The company has implemented cost-cutting restructuring measures in 2025 and maintains a strong balance sheet with $135 million in cash and no long-term debt. - Despite positive financial positioning, Amarin's single-drug dependency creates operational vulnerability compared to larger pharmaceutical companies with diversified portfolios.
- Amarin achieved significant operational improvements in Q4 2025, narrowing operating losses by 88% to $6.3 million while reducing operating expenses by 31% through strategic restructuring initiatives. - The company returned to positive cash flow ahead of schedule and ended 2025 with $302.6 million in cash and no debt, positioning it for sustained profitability in 2026. - VASCEPA/VAZKEPA is uniquely positioned to benefit from new ApoC-III therapies through payor-driven step therapy programs, similar to how ezetimibe experienced 15% annual growth following PCSK9 inhibitor launches. - The cardiovascular drug franchise now spans over 20 countries with proven efficacy, having been prescribed more than 25 million times and demonstrated a 25% reduction in cardiovascular events in the landmark REDUCE-IT trial.
- The US Solicitor General urged the Supreme Court to hear Hikma Pharmaceuticals' appeal challenging a ruling that found the company induced patent infringement through its generic Vascepa labeling. - The government argued that Hikma shouldn't be penalized for using a "skinny label" that accurately described their product as the generic version of Amarin's heart medication. - The case centers on Vascepa, a heart medicine approved in 2012 for treating excessive triglycerides and expanded in 2019 for additional cardiovascular indications. - The dispute highlights critical issues around generic drug labeling practices and patent protection in the pharmaceutical industry.
- Amarin Corporation will present new post hoc analyses from the REDUCE-IT trial and mechanistic studies of eicosapentaenoic acid (EPA) at the European Society of Cardiology Congress 2025 in Madrid, Spain. - The presentations will explore icosapent ethyl's cardioprotective effects through multiple mechanisms, including inflammation reduction, lipoprotein oxidation, and cardiovascular-kidney-metabolic syndrome risk reduction. - New data will examine the impact of icosapent ethyl on hospitalization risk and duration, major adverse cardiovascular events stratified by apolipoprotein B and triglyceride-rich lipoprotein-cholesterol levels. - Mechanistic studies will investigate EPA's effects on inflammasome activation, lipoprotein(a) oxidation, and pro-inflammatory protein expression in endothelial cells under oxidative stress conditions.
- HLS Therapeutics has secured a Product Listing Agreement with Nova Scotia Pharmacare for Vascepa (icosapent ethyl) reimbursement, effective July 1, 2025. - The drug will be covered as an exception status product for secondary prevention of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides. - This milestone expands Vascepa access to more than 95% of eligible patients covered by public plans and private insurance across Canada. - The agreement strengthens HLS's position as a leading Canadian cardiovascular-focused pharmaceutical company following recent portfolio expansions.
- Recordati has acquired exclusive licensing and supply rights to commercialize Vazkepa (icosapent ethyl) across 59 European countries in a deal worth up to $175 million with Amarin. - Vazkepa is the only treatment proven to reduce cardiovascular risk in statin-treated patients with elevated triglycerides, backed by the REDUCE-IT study involving over 8,000 patients. - The drug generated €12 million in net sales across 11 European countries in 2024 and is projected to exceed €40 million in revenues by 2027. - The agreement includes a $25 million upfront payment and potential milestone payments up to $150 million based on sales performance thresholds starting at €100 million annually.
